|
01 Apr 2022 |
Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix to accelerate strategic growth in Biopharmaceuticals and MedTech
|
|
31 Mar 2022 |
Myeloid Therapeutics and Prime Medicine Enter Into Exclusive Option and Research Collaboration to Develop and Accelerate Next-Generation RNA-based Gene-Editing Technology, RetroT™
|
|
29 Mar 2022 |
Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
|
|
23 Mar 2022 |
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%
|
|
22 Mar 2022 |
Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics
|
|
22 Mar 2022 |
Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
|
|
21 Mar 2022 |
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics
|
|
21 Mar 2022 |
Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
|
|
17 Mar 2022 |
Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
|
|
16 Mar 2022 |
Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
|
|
16 Mar 2022 |
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
|
|
12 Mar 2022 |
AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
|
|
10 Mar 2022 |
Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
|
|
10 Mar 2022 |
Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
|
|
09 Mar 2022 |
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
|
|
08 Mar 2022 |
Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients
|
|
08 Mar 2022 |
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
|
|
02 Mar 2022 |
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
|
|
02 Mar 2022 |
AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006
|
|
02 Mar 2022 |
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
|
|
01 Mar 2022 |
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
|
|
01 Mar 2022 |
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients
|
|
28 Feb 2022 |
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
|
|
25 Feb 2022 |
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
|
|
23 Feb 2022 |
Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases
|
